<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36967698</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Why we need a deeper understanding of the pathophysiology of long COVID.</ArticleTitle><Pagination><StartPage>393</StartPage><EndPage>395</EndPage><MedlinePgn>393-395</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(23)00053-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(23)00053-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Infection and Immunity, and Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. Electronic address: akiko.iwasaki@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putrino</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York City, NY, USA; Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>AI is a principal investigator in a decentralised phase 2 efficacy and safety study of nirmatrelvir and ritonavir in adult participants with long COVID (PAXLC; NCT05668091); is a consultant for RIGImmune, Xanadu Bio, Invisishield, and Paratus Bio; and is the vice president of the American Association of Immunologists. DP declares no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36967698</ArticleId><ArticleId IdType="pmc">PMC9928485</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(23)00053-1</ArticleId><ArticleId IdType="pii">S1473-3099(23)00053-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 doi: 10.1038/s41579-022-00846-2. published online Jan 13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2022 https://doi.org/101.093/cid/ciac722 published online Sept 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. Distinguishing features of long COVID identified through immune profiling. medRxiv. 2022 https://doi.org/101.101/20220.80.92.2278592 published online Aug 10. (preprint).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023 https://doi.org/10.1172%2FJCI163669 published online Feb 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A, Lu P, Geraghty AC, et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022;185:2452&#x2013;2468.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189143</ArticleId><ArticleId IdType="pubmed">35768006</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/post-acute sequelae of COVID-19 (PASC) Cardiovasc Diabetol. 2022;21:148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntur VP, Nemkov T, de Boer E, et al. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of patients with post-acute sequelae of COVID-19 (PASC) Metabolites. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9699059</ArticleId><ArticleId IdType="pubmed">36355108</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28:911&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>